21,853 Shares in Tyra Biosciences, Inc. $TYRA Purchased by PSP Research LLC

PSP Research LLC bought a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,853 shares of the company’s stock, valued at approximately $575,000. Tyra Biosciences comprises about 0.5% of PSP Research LLC’s investment portfolio, making the stock its 4th biggest position.

Other large investors also recently modified their holdings of the company. Federated Hermes Inc. grew its stake in shares of Tyra Biosciences by 586.3% in the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after purchasing an additional 1,841 shares during the last quarter. Chung Wu Investment Group LLC bought a new stake in Tyra Biosciences during the 4th quarter valued at approximately $53,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Tyra Biosciences by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after acquiring an additional 534 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Tyra Biosciences by 14.5% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after acquiring an additional 1,668 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Tyra Biosciences during the 3rd quarter valued at approximately $133,000. 84.14% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, Director Gilla Kaplan sold 14,295 shares of the business’s stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the completion of the transaction, the director directly owned 28,231 shares in the company, valued at $1,043,700.07. The trade was a 33.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 12.50% of the stock is currently owned by insiders.

Tyra Biosciences Stock Down 5.3%

Shares of TYRA opened at $33.78 on Wednesday. The business’s 50 day moving average price is $36.17 and its 200-day moving average price is $29.36. Tyra Biosciences, Inc. has a 52 week low of $8.75 and a 52 week high of $40.65. The stock has a market cap of $2.01 billion, a P/E ratio of -15.50 and a beta of 0.79.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). On average, equities analysts anticipate that Tyra Biosciences, Inc. will post -2.63 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on TYRA. Wolfe Research began coverage on Tyra Biosciences in a research report on Tuesday. They set a “peer perform” rating on the stock. Jefferies Financial Group lifted their price objective on Tyra Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday, February 3rd. Canaccord Genuity Group began coverage on Tyra Biosciences in a research report on Monday, April 6th. They set a “buy” rating and a $50.00 price objective on the stock. Guggenheim began coverage on Tyra Biosciences in a research report on Tuesday, April 14th. They set a “buy” rating and a $54.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tyra Biosciences presently has an average rating of “Moderate Buy” and an average price target of $46.50.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.